Alcon (NYSE:ALC) and RxSight (Nasdaq:RXST) announced that they entered into a non-exclusive intraocular lens (IOL) ...

Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies ...

Please provide your email address to receive an email when new articles are posted on . The historical paradigm of cataract surgery forced an absolute compromise: pristine distance vision with ...

LONDON — King Charles III will not live at Buckingham Palace after the completion of a 10-year, 369 million-pound ($487 million) refurbishment program as the monarchy seeks to increase public access ...

King Charles III will become the first British monarch to make his personal tax information public in a move aimed at increasing royal finance transparency. Buckingham Palace said the King himself ...

Monarch is a subscription-based personal finance app for tracking budgets, investments, and net worth. Key features include customizable budgeting, investment tracking, and collaboration tools for ...

Add Yahoo as a preferred source to see more of our stories on Google. LONDON (AP) — King Charles III reveals he paid 12.2 million pounds in 2024-2025 taxes, becoming 1st UK monarch to reveal tax ...

King Charles III will reveal his personal tax bill in a bid to improve transparency, Buckingham Palace told UK media on Saturday, as royal finances come under increasing public scrutiny. British ...

LONDON, United Kingdom — King Charles III will reveal his personal tax bill in a bid to improve transparency, Buckingham Palace confirmed to AFP on Sunday, as royal finances come under increasing ...

Charles released his tax information for the period he has been king of Britain as part of a push for greater transparency after the scandal involving the former Prince Andrew. By Megan Specia ...

Lip-reading specialist Nicola Hickling watched the live broadcast of the parade on Saturday and claimed that the monarch made a five-word confession to his wife during the royal carriage procession.

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 ...